Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Progestogens for Prevention of Preterm Birth

Slide: 23 of 29

Studies and Results Based on Formulation and Route of Administration

The authors of the comparative effectiveness review analyzed published study data by organizing it according to formulation and route of administration: intramuscular, oral, and vaginal.

Progestogen formulated for intramuscular administration (i.e., 17-hydroxyprogsterone) was used in nine studies. The risk of preterm birth was reduced to an odds ratio of 0.75, with a 95-percent confidence interval spanning from 0.60 to 0.90. The risk of fetal/neonatal mortality was unaffected, at an odds ratio of 1.11 with a 95-percent confidence interval spanning from 0.66 to 1.73. The strength of evidence was not rated.

Progestogen formulated for oral administration was used in three studies. The risk of preterm birth was reduced to an odds ratio of 0.56, with a 95-percent confidence interval spanning from 0.36 to 0.79. The risk of fetal/neonatal mortality was unaffected, at an odds ratio of 0.68 but with a statistically nonsignificant 95-percent confidence interval spanning from 0.04 to 2.17 (odds may be both greater and less than 1). The strength of evidence for these results was not determined.

Progestogen formulated for vaginal administration was used in four studies. The risk of preterm birth was reduced to an odds ratio of 0.76 , with a 95-percent confidence interval spanning from 0.57 to 0.98. The risk of fetal/neonatal mortality was unaffected, at an odds ratio of 0.77 but with a statistically nonsignificant 95-percent confidence interval spanning from 0.39 to 1.27 (odds may be both greater and less than 1). The strength of evidence for these results was not determined.